- Home
- OUST vs DBVT Comparison
OUST vs DBVT Comparison
Compare OUST & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OUST | DBVT |
|---|---|---|
| Founded | 2015 | 2002 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | OUST | DBVT |
|---|---|---|
| Price | $24.98 | $24.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $34.80 | $31.75 |
| AVG Volume (30 Days) | ★ 1.9M | 452.2K |
| Earning Date | 11-04-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $137,298,000.00 | $5,502,000.00 |
| Revenue This Year | $35.72 | $1,768.71 |
| Revenue Next Year | $35.65 | $1,028.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 30.20 | N/A |
| 52 Week Low | $6.34 | $3.80 |
| 52 Week High | $41.65 | $26.19 |
Technical Indicators
Market Signals| Indicator | OUST | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 48.27 | 72.78 |
| Support Level | $23.53 | $16.69 |
| Resistance Level | $28.08 | $18.40 |
| Average True Range (ATR) | 1.95 | 1.45 |
| MACD | -0.05 | 0.57 |
| Stochastic Oscillator | 17.92 | 92.59 |
Price Performance
Historical ComparisonAbout OUST Ouster Inc.
Ouster Inc is a provider of lidar sensors for the automotive, industrial, robotics, and smart infrastructure industries. Ouster's products include high-resolution scanning and solid-state digital lidar sensors, Velodyne Lidar sensors, and software solutions. The company operates in the Americas, Asia and Pacific, Europe, Middle East, and Africa regions. It derives maximum revenue from Americas.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.